Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
The company manufactures and supplies active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products, advance intermediates, fine ingredients, crop science ingredients, life science chemicals, and nutritional products.
Jubilant Pharmova Limited, is a listed public company incorporated on 21 June, 1978. It is classified as a public limited company and is located in U P, Uttar Pradesh. It's authorized share capital is INR 143.02 cr and the total paid-up capital is INR 15.93 cr.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2023 numbers.
823.23%
-36.46%
88.37%
-39.58%
64.44%
-51.17
8.13
-31.49
-4.05
7.37
-0.27
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(30)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Axis Bank Limited
No. of Loans: 1
Total Amount : 120.0 cr
HDFC Bank Limited
No. of Loans: 1
Total Amount : 100.0 cr
Bajaj Finance Limited
No. of Loans: 1
Total Amount : 100.0 cr
ICICI Bank Limited
No. of Loans: 1
Total Amount : 70.0 cr
RBL Bank Limited
No. of Loans: 1
Total Amount : 60.0 cr
Yes Bank Limited
No. of Loans: 1
Total Amount : 50.0 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Shyam Sunder Bhartia
Shareholder
|
00010484 | 47 years |
| Managing Director | Hari Shanker Bhartia
Shareholder
|
00010499 | 41 years |
| Director | Priyavrat Bhartia
Shareholder
|
00020603 | 8 years |
| Director | Vivek Mehra | 00101328 | 8 years |
| Director | Arun Seth
Shareholder
|
00204434 | 6 years |
| Director | Sushil Kumar Roongta | 00309302 | 8 years |
| Director | Harsh Mahajan | 00824227 | 1 years |
| Director | Shivpriya Nanda | 01313356 | 1 years |
| Director | Shirish Gundopant Belapure | 02219458 | 2 years |
| Director | Arjun Shanker Bhartia | 03019690 | 8 years |
| Whole-time Director | Arvind Chokhany
Shareholder
|
06668147 | 4 years |
| Kmp | Arvind Chokhany | <HIDDEN> | 2 years |
| Director | Ramakrishnan Arul | 08236356 | 1 years |
| Director | Kumar Ramamurthi | 09139426 | 2 years |
| Kmp | Naresh Kapoor | <HIDDEN> | 2 years |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| JUBILANT CLINSYS LIMITED | Uttar Pradesh | 2004 | ₹ 2.0 Cr |
| JUBILANT CHEMSYS LIMITED | Uttar Pradesh | 2004 | ₹ 8.2 Cr |
| JUBILANT BIOSYS LIMITED | Uttar Pradesh | 1998 | ₹ 252.1 Cr |
| JUBILANT INFRASTRUCTURE LIMITED | Uttar Pradesh | 2006 | ₹ 34.5 Cr |
| JUBILANT FIRST TRUST HEALTHCARE LIMITED | India | - | - |
| JUBILANT GENERICS LIMITED | Uttar Pradesh | 2013 | ₹ 2.6 Cr |
| Jubilant Life Sciences (USA) Inc. | United States | - | - |
| Jubilant Life Sciences (Shanghai) Limited | China | - | - |
| Jubilant Pharma NV | Belgium | - | - |
| Jubilant Pharmaceuticals NV | Belgium | - | - |
| PSI Supply NV | Belgium | - | - |
| Jubilant Pharma Holdings Inc. (formerly known as Jubilant Life Sciences Holdings Inc.) | United States | - | - |
| Jubilant Clinsys Inc. | United States | - | - |
| HSL Holdings Inc. | United States | - | - |
| Jubilant HollisterStier LLC | United States | - | - |
| Jubilant Pharma Limited (formerly known as Jubilant Pharma Pte. Ltd) | Singapore | - | - |
| Cadista Holdings Inc. | United States | - | - |
| Jubilant Cadista Pharmaceuticals Inc. | United States | - | - |
| Jubilant Biosys (BVI) Limited | Virgin Islands, British | - | - |
| Jubilant Biosys (Singapore) Pte. Ltd. | Singapore | - | - |
| Jubilant Discovery Services Inc. | United States | - | - |
| Jubilant Drug Development Pte. Ltd. | Singapore | - | - |
| Jubilant Life Sciences (BVI) Limited | Virgin Islands, British | - | - |
| Jubilant Life Sciences International Pte. Limited | Singapore | - | - |
| Jubilant Innovation (BVI) Ltd. | Virgin Islands, British | - | - |
| Jubilant Innovation Pte. Limited | Singapore | - | - |
| Draximage Limited, Cyprus | Cyprus | - | - |
| Draximage Limited, Ireland | Ireland | - | - |
| Draximage LLC. | United States | - | - |
| Jubilant DraxImage (USA) Inc. | United States | - | - |
| Deprenyl Inc., USA | United States | - | - |
| Jubilant DraxImage Inc. | Canada | - | - |
| 6963196 Canada Inc. | Canada | - | - |
| 6981364 Canada Inc. | Canada | - | - |
| DAHI Animal Health (UK) Limited | United Kingdom | - | - |
| Draximage (UK) Ltd. | United Kingdom | - | - |
| Jubilant Innovation (USA) Inc. | United States | - | - |
| JUBILANT INNOVATION (INDIA) LIMITED | Uttar Pradesh | 2007 | ₹ 5.0 L |
| JUBILANT DRAXIMAGE LIMITED | Uttar Pradesh | 2009 | ₹ 7.8 L |
| Draxis Pharma LLC | United States | - | - |
| Jubilant HollisterStier Inc. | United States | - | - |
| Jubilant Life Sciences (Switzerland) AG , schaffhhausen | Switzerland | - | - |
| Jubilant Drug Discovery & Development Services Inc. | Canada | - | - |
| VANTHYS PHARMACEUTICAL DEVELOPMENT PRIVATE LIMITED | Uttar Pradesh | 2009 | ₹ 22.5 Cr |
| Drug Discovery and Development Solutions Limited | Singapore | - | - |
| Jubilant Life Sciences NV | Belgium | - | - |
| Jubilant Pharma Trading Inc. | United States | - | - |
The incorporation date of JUBILANT PHARMOVA LIMITED is 21 June, 1978
The authorized share capital of JUBILANT PHARMOVA LIMITED is INR ₹ 143.0 Cr.
The paid-up capital of JUBILANT PHARMOVA LIMITED is INR ₹ 15.9 Cr.
The registered address of JUBILANT PHARMOVA LIMITED is BHARTIAGRAM GAJRAULAJYOTIBA PHOOLAY NAGAR U P Uttar Pradesh - 244223
The CIN number of JUBILANT PHARMOVA LIMITED is L24116UP1978PLC004624.
Expand
Delete
Collapse
See
details
